Literature DB >> 16417539

Refractory generalized seizures: response to corpus callosotomy and vagal nerve stimulation.

Maromi Nei1, Michael O'Connor, Joyce Liporace, Michael R Sperling.   

Abstract

PURPOSE: The vagal nerve stimulator (VNS) and corpus callosotomy can reduce seizure frequency when seizures are refractory to medications. However, the efficacy and safety of these two procedures have not been compared. This study evaluates the two procedures for generalized seizures.
METHODS: All patients with refractory generalized seizures (generalized tonic-clonic, tonic, or atonic) who underwent a corpus callosotomy (anterior or complete) (n = 53) without other forms of epilepsy surgery and those who underwent VNS placement (n = 25) were evaluated for this study. Seizure response and procedure complications were evaluated.
RESULTS: For those with a corpus callosotomy and generalized tonic-clonic seizures (n = 50), 79.5% had >or=50% decrease in the frequency of generalized tonic-clonic seizures, and 60% had >or=80% seizure reduction. For those with a VNS and generalized tonic-clonic seizures (n = 21), 50% had >or=50% seizure reduction, and 33% had >or=80% seizure reduction. Tonic and atonic seizures decreased after either VNS or a corpus callosotomy. The complication rate for corpus callosotomy was higher (21% all complications, 3.8% permanent) than that for VNS (8%; none permanent), but complications for both corpus callosotomy and VNS were rarely permanent.
CONCLUSIONS: Both corpus callosotomy and VNS are effective in reducing generalized seizures. Corpus callosotomy is associated with greater efficacy but higher risk for complications, although these were generally transient.

Entities:  

Mesh:

Year:  2006        PMID: 16417539     DOI: 10.1111/j.1528-1167.2006.00377.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  15 in total

1.  Electrical stimulation in epilepsy: vagus nerve and brain stimulation.

Authors:  Barbara C Jobst
Journal:  Curr Treat Options Neurol       Date:  2010-09       Impact factor: 3.598

2.  Treatment options in juvenile myoclonic epilepsy.

Authors:  Laura Mantoan; Matthew Walker
Journal:  Curr Treat Options Neurol       Date:  2011-08       Impact factor: 3.598

Review 3.  Medical management of Lennox-Gastaut syndrome.

Authors:  Aspasia Michoulas; Kevin Farrell
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

4.  When should corpus callosotomy be offered as palliative therapy?

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2010-01       Impact factor: 7.500

Review 5.  Neurosurgical approaches to pediatric epilepsy: Indications, techniques, and outcomes of common surgical procedures.

Authors:  Jonathan Dallas; Dario J Englot; Robert P Naftel
Journal:  Seizure       Date:  2018-11-16       Impact factor: 3.184

6.  Neurological results of the modified treatment of epilepsy by stimulation of the vagus nerve.

Authors:  Michael Vaiman; Eli Heyman; Gad Lotan
Journal:  Childs Nerv Syst       Date:  2017-07-08       Impact factor: 1.475

7.  Long-term results of vagus nerve stimulation in children and adolescents with drug-resistant epilepsy.

Authors:  Beata Majkowska-Zwolińska; Piotr Zwoliński; Marcin Roszkowski; Krzysztof Drabik
Journal:  Childs Nerv Syst       Date:  2012-01-06       Impact factor: 1.475

8.  Corpus callosotomy for treatment of pediatric refractory status epilepticus.

Authors:  Hansel M Greiner; Jan-Mendelt Tillema; Barbara E Hallinan; Katherine Holland; Ki-Hyeong Lee; Kerry R Crone
Journal:  Seizure       Date:  2012-02-11       Impact factor: 3.184

9.  Use of the newer antiepileptic drugs in pediatric epilepsies.

Authors:  Amy D Malphrus; Angus A Wilfong
Journal:  Curr Treat Options Neurol       Date:  2007-07       Impact factor: 3.598

10.  Long-term follow-up after callosotomy--a prospective, population based, observational study.

Authors:  Lina Stigsdotter-Broman; Ingrid Olsson; Roland Flink; Bertil Rydenhag; Kristina Malmgren
Journal:  Epilepsia       Date:  2013-12-24       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.